At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 22 enrolled
Drug / intervention
cinacalcet +1 moredrug
Likely dose
cinacalcet 30 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy of a Calcimimetic (Cinacalcet) in the Long Term Control of Patients With Primary Hyperparathyroidism
In Brief
A Phase 4 clinical trial evaluating cinacalcet and Alendronate for Hyperparathyroidism, Primary and Osteoporosis. Completed, enrolled 22 participants across 1 site.
Detailed Summary
To assess the efficacy and safety of treatment with cinacalcet and with cinacalcet plus alendronate in controlling bone loss induced by primary hyperparathyroidism.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHyperparathyroidism, Primary, Osteoporosis
CountriesItaly
Collaborators--
Timeline
Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMay 2008
Primary CompletionOct 2011
Study CompletionDec 2012
First PostedApr 2015
TodayJul 2026
First PostedApr 15, 2015
Enrollment StartMay 1, 2008
Primary CompletionOct 1, 2011
Study CompletionDec 1, 2012
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 11.2 years ago
Interventions
cinacalcetdrug
During Phase 1 (months 1-12): oral administration; 30 mg twice/day (dose to be increased if needed).
Alendronatedrug
During Phase 2 (months 13-24): oral administration; 70 mg once/week (in addition to cinacalcet 30 mg twice/day as during Phase 1).